GlassScriptPhysician profile
Emily Boegner
NPI 1760151955
$8,121.40
in general payments reported to CMS, 2019-2025
25 companies · $2,630 in 2025
The $2,630 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34.11 · 2022: $1,251 · 2023: $1,936 · 2024: $2,270 · 2025: $2,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,501 · Education: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,501.27 |
| Education | $335.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,323.28 | 2022-2025 | |
| Janssen Biotech, INC. | $879.06 | 2023-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $851.00 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $761.54 | 2022-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $637.47 | 2022-2025 | |
| Pfizer INC. | $545.22 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $535.63 | 2022-2025 | Sotyktu |
| Incyte Corporation | $402.97 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $320.85 | 2022-2024 | Taltz, Zepbound, Olumiant |
| Genzyme Corporation | $292.22 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $242.73 | 2021-2025 | Winlevi |
| Dermavant Sciences, INC. | $189.11 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $183.85 | 2023-2024 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $170.80 | 2023-2025 | Cabtreo, Arazlo |
| Verrica Pharmaceuticals INC. | $168.54 | 2024-2025 | Ycanth |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $147.14 | 2023-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $110.43 | 2023-2025 | Nemluvio, Aklief, Epsolay |
| Amgen INC. | $106.36 | 2023-2024 | Otezla |
| Lnhc, INC | $58.68 | 2025 | Zelsuvmi |
| Almirall LLC | $57.00 | 2022-2025 | Klisyri |
| Journey Medical Corporation | $55.48 | 2022-2025 | |
| Organon LLC | $24.69 | 2025 | Vtama |
| Botanix Sb INC | $24.21 | 2025 | Sofdra |
| Sebela Pharmaceuticals INC. | $17.24 | 2023 | Naftin |
| Vyne Pharmaceuticals INC. | $15.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Boegner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.